Brokerages Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Price Target at $34.60

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) have been assigned an average recommendation of “Buy” from the five research firms that are currently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $36.60.

A number of research firms have commented on KNSA. Jefferies Financial Group started coverage on Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Wedbush increased their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a report on Tuesday, July 23rd. JPMorgan Chase & Co. boosted their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Evercore ISI raised their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th.

Insider Transactions at Kiniksa Pharmaceuticals

In related news, COO Eben Tessari sold 17,500 shares of Kiniksa Pharmaceuticals stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total value of $470,925.00. Following the sale, the chief operating officer now owns 119,911 shares of the company’s stock, valued at approximately $3,226,805.01. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Eben Tessari sold 17,500 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total value of $470,925.00. Following the completion of the transaction, the chief operating officer now directly owns 119,911 shares of the company’s stock, valued at approximately $3,226,805.01. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John F. Paolini sold 60,692 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the transaction, the insider now owns 52,038 shares in the company, valued at $1,359,232.56. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 112,692 shares of company stock valued at $2,950,315 in the last ninety days. 54.57% of the stock is currently owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. CWM LLC raised its holdings in Kiniksa Pharmaceuticals by 443.0% in the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after acquiring an additional 1,998 shares during the period. nVerses Capital LLC bought a new stake in Kiniksa Pharmaceuticals in the 3rd quarter valued at $80,000. Lazard Asset Management LLC bought a new position in Kiniksa Pharmaceuticals during the 1st quarter worth $71,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Kiniksa Pharmaceuticals during the second quarter worth $100,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Kiniksa Pharmaceuticals by 65.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company’s stock valued at $195,000 after acquiring an additional 3,076 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Stock Down 0.7 %

Shares of KNSA stock opened at $22.86 on Friday. The stock’s fifty day simple moving average is $24.96 and its 200 day simple moving average is $22.65. Kiniksa Pharmaceuticals has a one year low of $14.12 and a one year high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $112.21 million during the quarter, compared to the consensus estimate of $111.51 million. During the same period in the previous year, the company posted ($0.20) EPS. The firm’s revenue for the quarter was up 67.4% compared to the same quarter last year. Equities research analysts expect that Kiniksa Pharmaceuticals will post -0.47 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.